Povidone-iodine Antisepsis for Strabismus Surgery (PASS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the efficacy of 5 % vs. 1.25 % povidone-iodine (PI) as preoperative antiseptic prior to strabismus surgery in children as a prophylaxis of endophthalmitis. Given the low rate of endophthalmitis the conjunctival bacterial flora rate is used as surrogate marker to determine the effectiveness of topical PI in reducing or eliminating bacteria from the ocular surface at the time of the surgery. Secondary objective is a reduction of the incidence of postoperative endophthalmitis after strabismus surgery in young children.
| Condition | Intervention | Phase |
|---|---|---|
|
Strabismus Surgery Endophthalmitis |
Drug: Preoperative conjunctival irrigation with 5% or 1.25% PI |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children |
- The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI. [ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ] [ Designated as safety issue: No ]
- Iodine excretion after surgery, assessed as urine iodine concentration per creatinine clearance. [ Time Frame: 24 hours postoperatively ] [ Designated as safety issue: No ]
- Postoperative erosion of the cornea and corneal oedema. [ Time Frame: within 24 hours postoperatively ] [ Designated as safety issue: No ]
| Enrollment: | 70 |
| Study Start Date: | September 2009 |
| Study Completion Date: | December 2012 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
-
Drug: Preoperative conjunctival irrigation with 5% or 1.25% PI
Background: Endophthalmitis after strabismus surgery in young children leads to blindness and loss of the affected eye. It is caused by conjunctival bacteria. PI solutions between 1% and 5% reduce the number of bacteria on the conjunctiva. The concentration used varies widely among clinics, from 1% to 5%. In vitro studies have shown that PI is paradoxically more effective at lower concentration, but in cataract surgery in elderly, 1% PI has been shown to be less effective than 5% PI. Dilution by tear fluid or binding of PI to proteins in tear fluid may lower its effectiveness. Since endophthalmitis after strabismus surgery especially affects young children and the bacterial flora of the conjunctiva in children is different from that in adults, the cataract PI study should be repeated in young children operated for strabismus.
Objective: To compare the efficacy of 5 % vs. 1.25 % povidone-iodine (PI) as preoperative antiseptic prior to strabismus surgery in children as a prophylaxis of endophthalmitis. Given the low rate of endophthalmitis the conjunctival bacterial flora rate is used as surrogate marker to determine the effectiveness of topical PI in reducing or eliminating bacteria from the ocular surface at the time of the surgery.
Design: The study is a multi-centre, prospective, randomized-controlled, parallel-groups, assessor-blind (microbiological assessments), investigator-initiated trial.
Study population: All children under 6 years of age attending the 15 participating clinics for routine strabismus surgery will be eligible for the study at the point that a strabismus operation is planned. The clinics (5 Dutch, 10 German) will each recruit approximately 20 patients. The minimum sample size is 2 x 100 patients.
Intervention: Diluted PI, 1.25% or 5%, will be prepared in a sterile fashion, and distributed in single-use dispensers. These will be coded for randomization. Before initiation of surgery, children randomized to the 5% PI group will have their conjunctival fornices irrigated with 5 ml PI 5%. Children randomized to the 1.25% PI group will have their conjunctival fornices irrigated with 5 ml PI 1.25%. Conjunctiva cultures for aerobic and anaerobic bacteria will be obtained (1) after general anesthesia has been established, (2) 5-10 min after PI irrigation, (3) after reattachment of the eye muscles and (4) after closing the conjunctiva with sutures.
Primary outcome: The difference in the mean numbers of bacterial colony forming units (CFUs) from pre-irrigation (l) to post-irrigation with PI (2-4).
Secondary outcome: Iodine excretion after surgery, assessed as urine iodine concentration per creatinine clearance.
Postoperative erosion of the cornea and corneal oedema. Both of these have been described as side-effects of PI use.
Nature and extent of the burden and risks associated with participation:
Risks are limited to the act of taking the four bacterial cultures, as both 1.25% PI and 5% PI are approved preoperative antiseptic applications of PI and both are used, rather indiscriminately, by the university departments of ophthalmology participating in the study.
Eligibility| Ages Eligible for Study: | up to 5 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Children attending for routine strabismus surgery are eligible for the study. Criteria for inclusion:
- Children < 6 years of age
- undergoing surgery for strabismus for the first time, including any recession and/or resection surgery of the medial and/or lateral rectus muscles.
- willing to take part in all aspects of the study with written informed consent on the study participation of the child provided by the parents.
Exclusion Criteria:
- Any history or current condition of hypersensitivity to iodine
- Children on topical antibiotic within the last 30 days
- Children with signs of acute conjunctivitis, blepharitis, dacryocystitis or respiratory infection within the last 30 days
- Children with asthma or similar chronic, obstructive pulmonary disorder
- Insufficiently treated amblyopia, i.e. a difference between the visual acuities of both eyes larger than 1 LogMARline.
- Neurological or psychiatric disorder, medication, other eye disorder, decreased visual acuity caused by brain damage or trauma.
Contacts and Locations| Germany | |
| Ernst Moritz Arndt University | |
| Greifswald, Germany, D-17487 | |
| Universitäts-Augenklinik | |
| Magdeburg, Germany, D-39120 | |
| Universitäts-Augenklinik Ludwig-Maximilian University | |
| Munich, Germany, D-80336 | |
| Netherlands | |
| Dept. Ophthalmology Free University Medical Center | |
| Amsterdam, Netherlands, NL-1007MB | |
| Dept. Ophthalmology Academical Medical Center | |
| Amsterdam, Netherlands, NL-1105AZ | |
| Dept. Ophthalmology | |
| Leiden, Netherlands, NL-2300RC | |
| Dept. of Ophthalmology St. Laurentius Ziekenhuis | |
| Roermond, Netherlands, NL-6040AX | |
| Dept. of Ophthalmology Erasmus Medical Center | |
| Rotterdam, Netherlands, NL3000CA | |
| Rotterdam Eye Hospital | |
| Rotterdam, Netherlands, 3011BH | |
| Principal Investigator: | Huibert J Simonsz, MD PhD | Erasmus Medical Center |
| Principal Investigator: | Herminia Miño de Kaspar, PhD | Universitäts-Augenklinik Ludwig-Maximilian University Munich Germany |
More Information
Publications:
| Responsible Party: | Prof. H.J. Simonsz M.D., Erasmus Medical Center Rotterdam |
| ClinicalTrials.gov Identifier: | NCT00461656 History of Changes |
| Other Study ID Numbers: | ABR 14357 |
| Study First Received: | April 17, 2007 |
| Last Updated: | March 4, 2013 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Erasmus Medical Center:
|
Antiseptic Povidone-Iodine |
Additional relevant MeSH terms:
|
Endophthalmitis Strabismus Eye Infections Infection Eye Diseases Ocular Motility Disorders Cranial Nerve Diseases Nervous System Diseases Povidone Iodine Povidone-Iodine |
Plasma Substitutes Blood Substitutes Hematologic Agents Therapeutic Uses Pharmacologic Actions Anti-Infective Agents, Local Anti-Infective Agents Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013